Intellia Therapeutics, a preclinical biotech, was ranked as the seventh worst performing IPO of the year, with negative returns of 22.6 percent. The Cambridge, Massachusetts-based developer of gene editing therapies, raised $108 million in May by offering 6 million shares at $18 per share, at the high end of the $16 to $18 range. The company is listed on the Nasdaq GM under the symbol NTLA.